MX2022013770A - Relaxinas modificadas y metodos de uso de las mismas. - Google Patents

Relaxinas modificadas y metodos de uso de las mismas.

Info

Publication number
MX2022013770A
MX2022013770A MX2022013770A MX2022013770A MX2022013770A MX 2022013770 A MX2022013770 A MX 2022013770A MX 2022013770 A MX2022013770 A MX 2022013770A MX 2022013770 A MX2022013770 A MX 2022013770A MX 2022013770 A MX2022013770 A MX 2022013770A
Authority
MX
Mexico
Prior art keywords
methods
relaxins
engineered
compositions
relaxin
Prior art date
Application number
MX2022013770A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Kruse
Sarah Cecilia Erlandson
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2022013770A publication Critical patent/MX2022013770A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2022013770A 2020-05-08 2021-05-07 Relaxinas modificadas y metodos de uso de las mismas. MX2022013770A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021814P 2020-05-08 2020-05-08
PCT/US2021/031260 WO2021226439A2 (en) 2020-05-08 2021-05-07 Engineered relaxins and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022013770A true MX2022013770A (es) 2023-04-03

Family

ID=78468429

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013770A MX2022013770A (es) 2020-05-08 2021-05-07 Relaxinas modificadas y metodos de uso de las mismas.

Country Status (10)

Country Link
US (1) US20230174610A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146681A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023524981A (cg-RX-API-DMAC7.html)
KR (1) KR20230008791A (cg-RX-API-DMAC7.html)
CN (1) CN115768801A (cg-RX-API-DMAC7.html)
AU (1) AU2021268355A1 (cg-RX-API-DMAC7.html)
CA (1) CA3180662A1 (cg-RX-API-DMAC7.html)
IL (1) IL297951A (cg-RX-API-DMAC7.html)
MX (1) MX2022013770A (cg-RX-API-DMAC7.html)
WO (1) WO2021226439A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
JP2024546877A (ja) * 2021-12-15 2024-12-26 メドイミューン・リミテッド ヘテロ二量体リラキシン融合物を使用した治療
EP4713001A2 (en) * 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835251A (en) * 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
US20110245469A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives
US9567386B2 (en) * 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2015038938A1 (en) * 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CN115837014A (zh) * 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof
SG10201912034UA (en) * 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Also Published As

Publication number Publication date
AU2021268355A1 (en) 2022-11-24
WO2021226439A3 (en) 2022-02-10
JP2023524981A (ja) 2023-06-14
WO2021226439A2 (en) 2021-11-11
US20230174610A1 (en) 2023-06-08
WO2021226439A8 (en) 2021-12-23
CN115768801A (zh) 2023-03-07
IL297951A (en) 2023-01-01
CA3180662A1 (en) 2021-11-11
EP4146681A2 (en) 2023-03-15
KR20230008791A (ko) 2023-01-16
EP4146681A4 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
PH12022551750A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
MY209609A (en) Immunomodulators, compositions and methods thereof
WO2021226439A8 (en) Engineered relaxins and methods of use thereof
WO2019209965A3 (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
PH12022500003A1 (en) Il-2 conjugates and methods of use to treat autoimmune diseases
JOP20230036A1 (ar) نواهض مستقبل أوريكسين بيروليدين سيكلوهيبتان
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12022552371A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
PH12022552738A1 (en) Compositions comprising nanoparticles, method of making and uses thereof
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2024006064A (es) Composicion cristalina de tildacerfont y metodos de uso y preparacion de la misma.
MX2022000712A (es) Moduladores de nlrp3.
SA522431748B1 (ar) طرق لإنتاج أرجيناز 1 ناتج بمعاودة الارتباط الجيني بشري واستخداماته
MX2022014506A (es) Cisteina proteasa.
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
SA521430793B1 (ar) أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر
WO2023114847A3 (en) Compositions and methods for treating disease
PH12022550277A1 (en) Biopharmacuetical compositions and related methods
MX2025001279A (es) Aril-triazolilo y antagonistas gpr84 relacionados y usos de estos
MX2025001280A (es) Antagonistas de gpr84 con piridona sustituidos y usos de estos